Tháng 2023: CAR-T-cell therapy is a novel and effective cancer treatment modality that has revolutionized the treatment of cancer, particularly blood cancers. This therapy achieves a therapeutic effect or cures disease by repairing or reconstructing genetic materials that have been damaged. Since Roseberg first isolated tumour-infiltrating lymphocytes (TILs) to treat melanoma in 1986, the development of modified T cell therapy has gained significant momentum. Since the FDA approved the first Liệu pháp CAR-T, Kymriah, in 2017, the CAR-T market has grown rapidly. According to Frost & Sullivan, the global CAR-T market size is projected to increase from USD 10 million in 2017 to USD 1.08 billion in 2020, and then to USD 9.05 billion in 2025, with a compound annual growth rate (CAGR) of 55% from 2019 to 2025, making it the fastest-growing segment of the global cell and gene therapies (CGT) market.
CAR-T therapy is one of CGT therapy’s subsegments. On the basis of the origin of T cells, CAR-T therapy can be divided into two categories. Autologous CAR-T-cell therapy, which employs the patient’s own immune cells, and allogeneic CAR-T-cell therapy, which employs T cells from donor blood or occasionally umbilical cord blood,. The majority of CAR-T therapies are autologous Liệu pháp tế bào T CAR, which typically involve the steps outlined below:
Bạn có thể muốn đọc: Liệu pháp tế bào CAR T ở Trung Quốc
1) Các tế bào T được lấy từ máu ngoại vi của bệnh nhân;
2) Viral vectors such as AAV then modify T cells with CAR genes that are directed against a specific cell-surface protein on cancer cells;
3) The modified CAR-T cells population is expanded according to the patient’s weight;
4) The expanded CAR-T cells are then reinfused back into the patient. The entire manufacturing procedure lasts between one and three weeks and requires GMP compliance in an ultra-clean environment.
CAR-T therapy has reached a level of success that has never been seen before in treating B-cell cancers that are resistant to or refractory to chemotherapy, including R/R, B-ALL, NHL, and MM. The effectiveness of treating solid tumours is also currently under investigation. CD19-targeting and BCMA-targeting CAR-T therapies achieve the greatest clinical success among all CAR-T therapies. Four of the six CAR-T therapies approved by the FDA target CD19, while two target BCMA.
The most significant advantage over small and large molecule drugs is that patients can replace lifelong treatment of chronic disease with a limited number of doses, or even just one.
The United States pioneered the development of the CAR-T industry. However, by the middle of the 2010s, China had learned quickly and was catching up to the United States. Principally, the key drivers can be attributed to the Chinese government’s support for the development of a CGT ecosystem comprised of biotech companies, academics, healthcare providers, investors, and the government. Following the prioritization of biotechnology in the thirteenth five-year plan, the Chinese government emphasized its strategy to accelerate the innovation and development of biotech industries, including cell therapy. In addition, pertinent ministries have issued encouraging action regulations.
Sau khi Ý kiến của Hội đồng Nhà nước về cải cách hệ thống đánh giá, xem xét và phê duyệt thuốc và thiết bị y tế được công bố vào năm 2015, thị trường vốn cũng trở nên sôi động. Với tốc độ tăng trưởng gộp hàng năm là 45%, các công ty trị liệu tế bào của Trung Quốc đã huy động được khoảng 2.4 tỷ USD tiền tài trợ từ năm 2018 đến năm 2021.
Bạn có thể muốn đọc: Chi phí trị liệu bằng tế bào CAR T ở Trung Quốc
The number of CAR-T therapy trials in China surpassed those in the United States by 2018 as a result of this thriving ecosystem. As of June 2022, Chinese companies had conducted 342 clinical CAR-T trials. Malignancies in the B lineage were among the most prevalent manifestations. Two CAR-T products have commercial applications: Cócarta in June 2021 and Relma-cel in September 2021, among numerous drug candidates.
Theo Frost & Sullivan, thị trường CAR-T trong nước dự kiến sẽ tăng từ 0.2 tỷ CNY vào năm 2021 lên 8 tỷ CNY vào năm 2025, sau đó lên 28.9 tỷ CNY vào năm 2030, với tốc độ CAGR là 45% từ năm 2022 đến năm 2030. Mặc dù thực tế là thị trường CAR-T của Trung Quốc vẫn còn ở giai đoạn sơ khai, một động lực mạnh mẽ tồn tại.
Although the two approved CAR-T products are from Sino-US joint ventures Fosun Kite and JW Terapeutics, domestic players have made breakthroughs and caught up to global players in recent years. Legend Biotech, IASO Biotherapeutics, and CARsgen Therapeutics all obtained NDA approval for their BCMA CAR-T products, establishing them as the leaders in BCMA CAR-T therapy. CD19 CAR-T products are a focus for Juventas Therapeutics, Gracell Biotechnologies, Hrain Biotechnology, ImunoPharm, Shanghai Cell Therapy Group, and numerous domestic companies. Juventas Therapeutics is the leader in Chinese CD19 Liệu pháp CAR-T now that the NMPA has accepted its NDA for CNCT19. CARsgen Therapeutics is a global leader in solid tumours, and CT041 is the first CAR-T candidate for treating solid tumours to enter Phase II các thử nghiệm lâm sàng. Bioheng Biotech và BRL Biotech (tiếng Trung: ) tạo ra các thị trường CAR-T dị sinh mới.
Bạn có thể muốn đọc: Liệu pháp tế bào CAR T cho bệnh đa u tủy ở Trung Quốc
